AbbVie stock (US00287Y1091): Q1 2026 earnings beat and Skyrizi, Rinvoq drive fresh momentum

AbbVie impressed with its Q1 2026 numbers: revenue climbed double?digit and adjusted EPS beat expectations, powered by immunology blockbusters Skyrizi and Rinvoq, while the share price recently pushed higher on the NYSE.

AbbVie delivered a solid start to 2026 as the biopharma group reported double?digit revenue growth and earnings above expectations, driven mainly by its immunology drugs Skyrizi and Rinvoq. For the first quarter of 2026, AbbVie generated around 15 billion USD in revenue, up 12.4 percent year over year, and posted adjusted earnings per share of 2.65 USD, both ahead of consensus, according to Ad-hoc-news as of 05/08/2026. The strong report coincided with a noticeable move in the stock: AbbVie shares recently traded as high as 215.80 USD and last changed hands near 213.77 USD on the NYSE, roughly 2.1 percent above the prior close, according to MarketBeat as of 05/19/2026.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AbbVie Inc.
• Sector/industry: Biopharmaceuticals
• Headquarters/country: North Chicago, United States
• Core markets: Immunology, oncology, neuroscience, aesthetics
• Key revenue drivers: Skyrizi, Rinvoq, aesthetics portfolio
• Home exchange/listing venue: NYSE (ticker: ABBV)
• Trading currency: US dollar

AbbVie Inc.: core business model

AbbVie focuses on the research, development and commercialization of prescription medicines for chronic and serious diseases. The company was spun off from Abbott Laboratories in 2013 and since then has built a diversified portfolio across immunology, oncology, neuroscience and aesthetics. Its strategy blends internal R&D with business development, including licensing and acquisitions, to support a broad late?stage pipeline. In recent years, AbbVie has increasingly emphasized durable, high?growth franchises with patent protection extending well into the next decade.

Historically, AbbVie was known for its blockbuster immunology drug Humira, which generated tens of billions of dollars in sales over its peak years. With biosimilar competition now eroding Humira revenue in key markets, the company has pivoted toward newer products such as Skyrizi and Rinvoq to sustain growth. These therapies target inflammatory conditions like psoriasis, psoriatic arthritis and rheumatoid arthritis and are positioned as next?generation treatments with differentiated efficacy or dosing profiles. At the same time, AbbVie is working to expand indications for both drugs, which can increase the addressable patient population over time.

Beyond immunology, AbbVie has meaningful exposure to neuroscience through treatments for conditions such as migraine and psychiatric disorders, and to oncology through hematologic cancer drugs. The acquisition of Allergan in 2020 also gave AbbVie a leading aesthetics business centered on Botox and dermal fillers. This mix of therapeutic areas provides diversification across cash?pay and reimbursed markets, as well as across different economic cycles. For US investors, AbbVie’s model combines the defensive traits of a large?cap pharmaceutical company with pockets of higher?growth specialty products.

Main revenue and product drivers for AbbVie Inc.

In the latest reported quarter, Skyrizi and Rinvoq stood out as AbbVie’s primary growth engines. Management highlighted that revenue growth in Q1 2026 was largely driven by these two immunology therapies, which continue to gain share in their respective indications, according to Ad-hoc-news as of 05/08/2026. Skyrizi is approved for conditions such as plaque psoriasis and Crohn’s disease, while Rinvoq targets rheumatoid arthritis, ulcerative colitis and other inflammatory diseases. Label expansions, favorable clinical data and physician familiarity have supported rising prescriptions, particularly in the US market where pricing remains a key revenue driver.

At the same time, AbbVie’s aesthetics portfolio, inherited from Allergan, provides a substantial and growing stream of cash flows. Products such as Botox Cosmetic and dermal fillers serve largely discretionary demand, but the segment has shown resilience and an ability to rebound quickly after periods of macroeconomic weakness. Recent job postings for roles like Business Development Manager in facial aesthetics and Allergan Practice Consultant suggest that AbbVie continues to invest in field?based commercial capabilities to deepen relationships with clinics and aesthetic practices in the US, as reflected in descriptions on the company’s careers page, according to AbbVie careers as of 05/10/2026.

Another important contributor is AbbVie’s neuroscience and oncology portfolio, including treatments for migraine and hematologic malignancies. While not every product in these categories is growing at the same pace, the segment overall helps balance the company’s reliance on immunology. AbbVie also maintains a sizable pipeline of investigational therapies at different clinical stages, designed to replenish revenue as older drugs face patent expirations. For equity investors following the US healthcare sector, the ability of Skyrizi and Rinvoq to offset Humira’s decline, combined with contributions from aesthetics and neuroscience, is central to assessing AbbVie’s medium?term earnings trajectory.

Conclusion

AbbVie enters 2026 with solid operational momentum: first?quarter revenue and adjusted earnings surpassed expectations, fueled principally by immunology blockbusters Skyrizi and Rinvoq and supported by contributions from the aesthetics and neuroscience franchises. The recent share price strength on the NYSE underlines that investors are closely watching how quickly these newer products can compensate for the ongoing erosion of Humira sales. At the same time, pipeline progress, regulatory decisions and competitive dynamics in key disease areas will likely play a major role in shaping AbbVie’s long?term growth profile. For US?focused investors in the healthcare sector, AbbVie represents a large?cap biopharma name with significant exposure to chronic disease treatments and a diversified portfolio, but also with typical sector uncertainties around pricing, regulation and clinical risk.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.